Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1B | Q01064 | 1/20 | 0.41 |
| ▸ | KLKB1 | P03952 | 8/20 | 0.39 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.38 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.38 |
| ▸ | CACNA1I | Q9P0X4 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6837484 | 0.87 | CACNA1G (0.40) | KLKB1CACNA1GCACNA1HCACNA1IKMT2A | |
| SCHEMBL369607 | 0.87 | KLKB1 (0.47) | KLKB1CACNA1GCACNA1HCACNA1IKMT2A | |
| SCHEMBL370025 | 0.85 | CACNA1G (0.39) | KLKB1CACNA1GCACNA1HCACNA1IKMT2A | |
| SCHEMBL368607 | 0.85 | CACNA1G (0.41) | KLKB1CACNA1GCACNA1HCACNA1IKMT2A | |
| SCHEMBL371196 | 0.83 | PDE1B (0.42) | PDE1BKLKB1CACNA1GCACNA1HCACNA1I | |
| SCHEMBL370299 | 0.82 | AADAT (0.43) | KLKB1CACNA1GCACNA1HCACNA1IKMT2A | |
| SCHEMBL2537359 | 0.82 | CACNA1G (0.42) | KLKB1CACNA1GCACNA1HCACNA1IKMT2A | |
| SCHEMBL370679 | 0.80 | L3MBTL1 (0.44) | KLKB1CACNA1GCACNA1HCACNA1IKMT2A | |
| SCHEMBL368611 | 0.79 | CACNA1G (0.42) | KLKB1CACNA1GCACNA1HCACNA1IKMT2A | |
| SCHEMBL369366 | 0.79 | CACNA1G (0.40) | KLKB1CACNA1GCACNA1HCACNA1IKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130252944-A1 | NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERCK SHARP & DOHME CORP. | 2013-09-26 | — | — | US | disclosed |
| EP-2593277-A2 | NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX Pharma S.A. (CH) | 2013-05-22 | — | — | EP | disclosed |
| WO-2012009000-A2 | NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA S.A. (CH) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252944-A1 | NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM4, GRM1, GRM3 | PDE1B 363/4885KLKB1 4667/4885CACNA1G 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.